Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Barinthus Biotherapeutics plc (BRNS) is a Biotechnology company based in GB with a market capitalization of $24.8M. Free cash flow was negative at -$48M. This page tracks BRNS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 105 employees · IPO Apr 30, 2021
Valuation
Valuation & price
$0.68as of May 26, 2026· -64.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.33
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$24.8M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$48M
Free cash flow (USD)
-$59.2M
Net debt
Net cash position
3.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 30, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Barinthus Biotherapeutics plc's market cap?
Barinthus Biotherapeutics plc (BRNS) has a market capitalization of $24.8M.
What is BRNS's P/E ratio?
A meaningful P/E ratio is not available for BRNS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is BRNS's price-to-book (P/B) ratio?
BRNS trades at 0.33 times book value per share.
Are insiders buying BRNS stock?
SEC Form 4 filings show no open-market insider buys at Barinthus Biotherapeutics plc in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.